How it works:
Gefitinib selectively inhibits the EGFR tyrosine kinase, disrupting intracellular signalling pathways critical to tumour cell proliferation and survival. It is particularly effective in patients whose tumours harbour activating mutations in the EGFR gene, making it a key option in first-line treatment.
Recommended for:
Patients with NSCLC and confirmed EGFR mutation
First-line therapy in treatment-naïve patients
Alternative in patients intolerant to chemotherapy
Patients undergoing personalised medicine guided by molecular testing
NSCLC with EGFR mutation
Locally advanced or metastatic lung cancer
Recurrent EGFR-positive lung tumours
Take orally once daily at the same time, with or without food. The standard dose is 250mg daily. Regular monitoring of liver function, dermatological symptoms and pulmonary side effects is essential throughout treatment.
Hypersensitivity to gefitinib or excipients
Pregnancy and breastfeeding
Severe hepatic impairment
Concomitant use of strong CYP3A4 inducers
Skin reactions: rash, itching, dryness
Diarrhoea, nausea
Fatigue
Elevated liver enzymes
Rare: interstitial lung disease
Possible allergic reactions
